Objective: A randomized, crossover, double-blinded placebo-controlled and non-blinded active drug-controlled, comparative clinical trial was conducted to evaluate the efficacy and safety of sublingual fentanyl tablet. Methods: Subjects were patients treated with strong opioids at fixed intervals for chronic cancer pain and with oral morphine as rescue medication for breakthrough pain. Sublingual fentanyl was administered at doses that were 1/25th (high dose) and 1/50th (low dose) of the dose of rescue morphine and was compared with placebo and oral morphine. The primary endpoint was pain intensity difference at 30 min after administration. (Clinical Trials Government; NCT00684632). Results: Fifty-one patients were enrolled in the investigation. Their mean pain intensity in visual analog scale before rescue medication prior to the investigation was 60.96 (16.44, standard deviation) mm. Compared with placebo, the low and high doses of sublingual fentanyl showed significant analgesic effects (least squares mean difference, 4.54 and 8.49 mm; P = 0.014, P < 0.001, respectively). Adverse reactions were observed in 17.6%, the most common being constipation, nausea and somnolence. The incidence of adverse reactions during the high-dose administration period was higher than that during the low-dose and active control drug administration periods. Conclusions: Patients treated with strong opioid analgesics at fixed intervals for chronic cancer pain and with oral morphine at doses up to 20 mg as rescue medication were investigated. The doses of sublingual fentanyl to treat breakthrough pain were determined from rescue morphine doses by use of conversion ratios. In these patients, administration of sublingual fentanyl at doses determined by a conversion ratio of 1/50 was effective and safe. Further studies are needed to validate the use of this conversion method.
Introduction
The alleviation of breakthrough cancer pain (BTcP) is one of the challenging issues in the treatment of cancer pain even with the widespread use of opioids as recommended by the WHO. BTcP is defined as a transitory exacerbation of pain in cancer patients whose pain is otherwise stable by receiving chronic around-the-clock opioid therapy (1, 2) . The prevalence of BTcP is high and it negatively affects patients' quality of life. Although temporal characteristics of BTcP may vary, typically it has a rapid onset and a relatively short duration (3) .
It is common practice to administer 'as-needed' rescue opioid medication to relieve BTcP. Oral morphine and oxycodone have long been used for this purpose (4) . However, in many cases, the pharmacokinetic/pharmacodynamic profiles of such oral opioids do not match the temporal profiles of BTcP (1, 4) , resulting in inadequate relief of BTcP (1) . Transmucosal fentanyl formulations were developed to possibly meet such needs. These formulations allow fentanyl to be rapidly absorbed across the oral/nasal mucosa and avoid first-pass metabolism, thus can produce rapid onset analgesia that may match the temporal profile of BTcP. The first clinically available formulation was oral transmucosal fentanyl citrate (OTFC), which is composed of a lozenge with a handle used to rub against the inner cheek (5). It has been shown to be effective in relieving BTcP but presents a large interindividual variability in pharmacokinetic parameters in part due to swallowing of the drug (5, 6) . In addition, it may not be ideal for patients with oral irritations (5) . Recently, other formulations for oral/ nasal transmucosal delivery of fentanyl have become available, one of which is the sublingual fentanyl orally disintegrating tablet (SFT, Abstral ® , Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.). SFT utilizes a new formulation system for rapid disintegration comprised of an ordered mixture of fine fentanyl particles attached to coarser excipient carrier particles with a bioadhesive component also added to the carrier particle (6) . A study showed that inter-individual variability of pharmacokinetic parameters was smaller compared with that of OTFC reported by others, suggesting that SFT may allow more reliable transmucosal absorption and less swallowing of fentanyl than OTFC (7, 8) . The first quantifiable drug concentration after administration of a single dose of SFT 100-800 µg to healthy Japanese adults was at 0.08-0.25 h, and the time to reach maximum plasma concentration was 0.51.0 h, which indicated rapid absorption of fentanyl through the oral mucosa (9) . A survey of practicality, including the ease of use, of SFT, buccal tablets and nasal spray, was conducted in cancer patients. The results showed that SFT was the most practical (10) . Multiple studies have shown the lack of correlation between the around-the-clock basal opioid doses and the doses of transmucosal fentanyl formulations for treatment of BTcP (11, 12) and concluded that titration from a low dose is needed to determine the fentanyl dose unlike oral opioids given for BTcP (13, 14) . Although titration from a low dose is obviously a safe method, it may be time-consuming and pose practical problems such as reduction of compliance on the part of the patient. In a multicenter study on OTFC, the authors showed that the effective OTFC dose determined by titration correlated with the regular oral rescue opioid dose taken by the patient (11) , and thus the regular rescue dose was a moderate predictor of the effective OTFC dose. If the regular oral rescue dose could be used to determine the dose of transmucosal fentanyl formulations, this would benefit the patient. This study was a multicenter Phase III trial of SFT for the treatment of BTcP to examine the efficacy and safety of SFT at doses determined from morphine rescue doses by use of conversion ratios.
Patients and methods

Study design
This was a randomized, crossover, double-blinded placebo-controlled and non-blinded active drug-controlled, comparative Phase III clinical trial. Twenty-five study centers distributed throughout Japan participated in this trial.
This trial was approved by the institutional review board of each study center and was performed in accordance with the Helsinki Declaration and in compliance with Good Clinical Practice. Written informed consent was obtained from all subjects after they had received an explanation for this trial.
Inclusion and exclusion criteria
Patients who met the following criteria were included in this trial. They were cancer patients aged from 20 to 80 years; patients with a constant daily dose of an opioid analgesic administered at fixed intervals (oral morphine preparation, oral oxycodone preparation or fentanyl transdermal preparation); patients who were receiving a single dose of 5, 10, 15 or 20 mg of an oral morphine preparation to treat BTcP at a frequency of 0.5 times a day (once in 2 days) or more and three times a day or less on average to control the pain; patients who were expected to maintain a constant daily dose of around-the-clock opioid analgesic from the initiation of the observation phase to the end of the study; and patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 or lower.
Patients who met any of the following criteria were excluded from this trial: patients who experienced intolerable adverse drug reactions to opioid analgesics; patients with serious respiratory dysfunction, bradyarrhythmia, hepatic dysfunction, renal dysfunction or asthma; and patients who were likely to have respiratory depression from increased intracranial pressure, head trauma or brain tumor.
Endpoints
The primary endpoint of this trial was pain intensity difference at 30 min after administration (PID30). PID30 is defined as the difference in pain intensity at 30 min after the administration of the investigational product from that immediately before administration. Visual analog scale (VAS) was used to evaluate the pain intensity. Each subject was instructed to indicate his/her pain level on a 100 mm long horizontal line, the left end of which represented no pain (0 mm) and the right end represented the most severe foreseeable pain (100 mm). The investigators measured the distance from the left end.
The secondary endpoints were PID60, pain relief at 30 and 60 min after administration (PR30 and PR60), need of additional dose at 30 min after administration of the investigational product and overall evaluation at 60 min after the administration of the investigational product. For evaluation of pain relief, each subject selected an appropriate pain relief score after each administration from the following five options: '4, Not relieved at all'; '3, Not sufficiently relieved'; '2, Fairly relieved'; '1, Considerably relieved'; and '0, Completely relieved.' Each subject was requested to determine the overall evaluation of the investigational product using the following five-rank scale: '4, Very poor'; '3, Poor'; '2, Fair'; '1, Good'; and '0, Very good.'
Observation phase
Patients who provided written informed consent entered the observation phase. Any four consecutive days from the day after providing written informed consent were defined as the observation phase. For all evaluable episodes of BTcP during the observation phase, evaluation using the VAS was performed before and after administration of the oral morphine preparation, which had been already prescribed for BTcP at the time of informed consent. Subjects who showed an analgesic effect of the oral morphine entered the investigation phase, that is, those whose VAS score immediately before administration was 30 mm or more, which was reduced by 18 mm or more and by one-third or more at 30 min after administration, on average for the 2 or more doses of the oral morphine preparation during the observation phase.
Investigation phase
The investigation phase was divided into three administration periods in which two different doses of SFT and active control were tested in a random order. The dose of SFT was calculated from the single dose of oral morphine preparation used during the observation phase by use of conversion ratios of 1/25 (high dose) and 1/50 (low dose), which were determined from a prior Phase II study (Table 1) . To limit the single dose of SFT to not >800 µg (maximum dose used in Japan), patients treated with a single dose of oral morphine at >20 mg were not included in this trial. The investigational product was administered three times in each administration period (nine times in total) to treat BTcP. During the high-dose and low-dose administration periods, two doses of SFT and one dose of placebo (three doses in total) were sublingually administered in a randomized manner under double-blinded condition. Three doses of the oral morphine preparation used during the observation phase were administered as an active control drug. The investigators and patients were not blinded as to which administration period was underway.
Statistical analysis
The primary analysis included analysis of covariance in a full analysis set (FAS), using a mixed effect model for PID30 using drug (high dose, low dose, active control drug and placebo), group (A-F), administration period and VAS before administration as fixed effects and subject as a random effect. The groups (A-F) corresponded to the order predetermined to administer any of the high dose, low dose or active control drug in each administration period. The P value for the null hypothesis that there was no difference from placebo was calculated for the high dose, low dose and active control drug. The least squares mean difference against the active control drug and its 95% confidence interval were calculated for the high dose and low dose. The non-inferiority to the active control drug was considered when the lower limit of the 95% confidence interval for the difference in PID30 from the active control drug was above −10 mm.
We planned to determine the superiority to the placebo and noninferiority to the active control drug according to the following procedure on the basis of the hierarchical structure of multiple hypotheses and its multiplicity, assuming that the SFT is effective and the effect is dose responsive: (1) superiority of the high dose to the placebo, (2) superiority of the low dose to the placebo, (3) non-inferiority of the high dose to the active control drug and (4) non-inferiority of the low dose to the active control drug. The superiority of the high dose to the placebo was considered verified when the above (1) was established, and that of the low dose to placebo was considered verified when the above (1) and (2) were established. The non-inferiority of the high dose to the active control drug was considered verified when the above (1) and (3) were established, and that of the low dose to the active control drug was considered verified when all the above (1)- (4) were established.
Target sample size was determined on the basis of the noninferiority of 1/50th dose to the active control drug, requiring the largest number of subjects among the hypotheses verified in this trial. With the difference in PID30 from the active control drug for low dose estimated to be 3 mm and intra-individual variance 200 mm 2 , the number of evaluable subjects required to obtain an ∼90% probability of showing non-inferiority to the active control drug was calculated at 6 per group, and 36 in total. Considering possible dropouts resulting in data missing, it was determined that the number of subjects would be 8 per group, and 48 in total. PID60 was analyzed using the same model as that for analysis of PID30. For PR30, PR60 and overall evaluation, the analysis of variance based on a mixed effect model was performed using drug, group and administration period as fixed effects and subject as a random effect. For the need of additional dose, a Cochran-MantelHaenszel (CMH) test using subject as a stratum was performed for the null hypothesis that there was no difference from the placebo for the high dose and low dose.
The following analysis sets were defined. An FAS consisting of subjects treated with the investigational product at least once and for whom the primary endpoint was recorded at least once in any administration period was used as an analysis set for the primary and secondary endpoints. A safety set (SS) consisting of subjects treated with the investigational product at least once and for whom any safety data were recorded after registration was used to evaluate safety.
Results
Disposition of subjects and subject background
The disposition of subjects and reasons for discontinuation and dropout are shown in Fig. 1 . Of the 94 subjects who entered the observation phase, 43 dropped out during the observation phase, and 51 entered the investigation phase. After inclusion in the investigation phase, 4 subjects discontinued and 47 completed the trial. All the subjects who entered the investigation phase were included in the FAS and SS.
The background of 51 subjects treated with the investigational product is summarized in Table 2 The most frequent primary disease (tumor) was lung cancer in 12 subjects (23.5%), followed by large intestinal cancer in 10 (19.6%), breast cancer in 7 (13.7%) and urological cancer in 6 (11.8%). The most common site of cancer pain was the back in 18 patients (35.3%), followed by the abdomen and anterior chest each in 16 patients (31.4%) and lumbar in 14 patients (27.5%). Opioid analgesics administered at fixed intervals during the observation phase included morphine in 7 patients, oxycodone in 19 and fentanyl in 25, which were used at a mean dose of 54. 
Safety
In this trial, the safety of SFT could not be compared with that of the placebo because two doses of SFT and one dose of placebo were administered during the high-dose and low-dose administration periods in a randomized manner for treating BTcP.
Nine of 51 subjects (17.6%) in the SS experienced adverse drug reactions ( Table 4 ). The most common adverse drug reactions were constipation, nausea and somnolence in 3 subjects each (5.9%), all of which were opioid-specific. One subject (2.0%) experienced nausea and vomiting, which led to discontinuation of the investigational product. Another subject (2.0%) experienced respiratory depression, which led to temporary suspension of the investigational product. The causal relationship of these adverse drug reactions in the two subjects to the active control drug was denied by the investigator because these adverse reactions developed before the subjects received the drug, but relationship to SFT was not denied. In the former subject, nausea and vomiting occurred during the high-dose administration period and resulted in the discontinuation of the investigational product after temporary suspension. Vomiting resolved after the temporary suspension of the investigational product, and nausea resolved after discontinuation of the investigational product. The latter subject who presented respiratory depression was treated with 800 µg during the high-dose administration period. The subject was able to breathe sufficiently in response to the physician's call. Respiratory depression resolved after temporary suspension of the investigational product. This subject did not experience respiratory depression during the low-dose or active control drug administration period.
Adverse drug reactions developed in 6 of 51 subjects (11.8%), 3 of 49 (6.1%) and 3 of 48 (6.3%) during the high-dose, low-dose and active control drug administration periods, respectively. The incidence of adverse drug reactions during the high-dose administration period was higher than that during the low-dose and active control drug administration periods, and no difference was found between the low-dose administration period and active control drug administration period (Table 4) . Adverse drug reactions experienced by more than one subject included somnolence in three subjects (5.9%) during the highdose administration period. However, all the adverse drug reactions observed during the low-dose and active control drug administration periods developed in a single subject.
Discussion
The dose of oral opioid preparations used to treat BTcP is calculated as a proportion of the daily dose of opioid analgesics administered at The dose of each opioid administered at fixed intervals is summarized for subjects treated with the opioid. The dose of transdermal fentanyl is calculated from average absorption rate.
BMI, body mass index; VAS, visual analog scale.
fixed intervals (15, 16) . However in the case of OTFC, multiple studies showed that the effective dose to treat BTcP determined from titration does not correlate to the daily around-the-clock dose and recommended dose titration from a low dose to determine the optimal dose (11, 12) . The reason for this discrepancy is not known. Since the dose calculation from the daily dose of scheduled opioid regimen is based on anecdotal observations, it may be possible that careful titration of oral opioids to treat BTcP may also result in doses that are not proportional to the daily doses. Nonetheless, the proportionate doses of oral opioids used as rescue medication have been safely used and are clinically effective. This method to determine the rescue dose is practical and benefits the patient by its promptness. Although dose titration to determine the dose of transmucosal fentanyl formulations is obviously a safe method, it may be time-consuming, and may delay pain relief and reduce patients' compliance (17) . Recent reports showed that OTFC and other transmucosal fentanyl formulations including SFT at doses proportional to the basal opioid regimen were safe and effective for the treatment of BTcP (18) (19) (20) . Thus, how the dose of transmucosal fentanyl formulations to treat BTcP should be determined remains unresolved. Since many patients with BTcP are initially treated with oral opioids, calculating the dose of transmucosal fentanyl preparations from this dose may be a practical method. This study is the first to examine the efficacy and safety of a transmucosal fentanyl preparation administered at a dose converted from the oral dose of morphine used to treat BTcP. On the basis of the data obtained in a Phase II clinical trial, we set the doses of SFT in this trial at 1/25th and 1/50th of the dose of oral morphine to evaluate the efficacy and safety of SFT administered to cancer patients who were treated with a strong opioid analgesic at fixed intervals for their chronic cancer pain and with oral morphine for BTcP.
Our results of PID30 calculated in 51 subjects in the FAS showed that the high and low doses of SFT were superior to the placebo and non-inferior to the active control drug. Common adverse drug reactions, including constipation, nausea and somnolence, were observed. However, they are all known events for opioid analgesics, and no new safety concerns were noted. When SFT was administered at the high dose, 1 subject (2.0%) experienced nausea and vomiting leading to the discontinuation of the investigational product and another (2.0%) experienced respiratory depression leading to the temporary suspension of the investigational product. These adverse drug reactions in the two subjects resolved after discontinuation or temporary suspension of the investigational product. Since the dose of the oral morphine in the subject with respiratory depression was 20 mg for the BTcP during the observation phase, the subject was treated at 800 µg during the high-dose administration period and experienced respiratory depression after the first dosing at 800 µg. The subject did not experience respiratory depression during the low-dose or active control drug administration. Although five subjects other than the subject above were treated at 800 µg, none of them experienced respiratory depression. At the high dose of SFT, the incidence of somnolence was higher than with the active control drug. On the other hand, no difference was observed in the incidence of adverse drug reactions between the low dose of SFT and the active control drug, and respiratory depression did not occur at the low dose. These results indicated that when SFT was used at a dose converted from a single dose of oral morphine (up to 20 mg), an analgesic effect appeared to be safely obtained by use of the conversion ratio of 1/50, but the conversion ratio of 1/25 may result in overdosing. It should be noted that, although the doses determined from the lower conversion ratio were demonstrated to be safe and effective, it was not shown whether the analgesic effects obtained were adequate. Higher doses might have been required to obtain adequate analgesia in some cases. In such cases, titration from the determined dose may be needed to optimize the dose. Nonetheless, this method may expedite the process of dose determination.
A limitation of this trial is that patients were confined to those treated with up to 20 mg of oral morphine for BTcP treatment. Patients treated with higher doses of oral morphine and those treated with oral oxycodone for BTcP treatment were not included in this trial. Furthermore, the sample size studied was limited. Further studies are needed to evaluate the validity of this conversion method. It should also be noted that patients above the age of 80 years old were not included in this trial. The use of SFT in such elderly patients has not been investigated and there is not enough safety and dosage information available regarding elderly patients. Thus, maximum caution should be exercised, especially for respiratory depression, when SFT is to be administered to such patients.
Conclusion
This study showed that, in patients who were treated with strong opioid analgesics at fixed intervals for their chronic cancer pain and with oral morphine at doses up to 20 mg as rescue medication for BTcP, administration of SFT to treat BTcP at doses determined from the doses of the rescue oral morphine by use of a conversion ratio of 1/50 was effective and safe. Further studies are needed to validate the use of this conversion method to determine the dose of SFT.
